Articles on this Page
- 06/11/10--05:31:_Deal of the day: GSK in...
- 07/07/10--05:17:_Deal of the day: Aspen...
- 07/30/10--02:39:_Shareholders (and...
- 08/12/10--06:25:_Ranbaxy: is India’s...
- 08/27/10--00:13:_India: from...
- 09/16/10--09:45:_Pharma companies reveal...
- 10/20/10--10:30:_Deal of the day: India-US...
- 11/04/10--10:30:_Deal of the day:...
- 11/15/10--07:33:_Brazilian drugmaker snubs...
- 12/03/10--05:45:_West’s drugmakers look...
- 12/13/10--00:51:_Deal of the day:...
- 04/08/11--05:08:_Deal of the day: Taisho...
- 05/16/11--01:30:_Shanghai Pharma prices HK...
- 05/17/11--09:23:_Indian pharma sector:...
- 10/04/11--01:30:_Moroccan tonic for Hikma
- 11/30/11--06:44:_Ranbaxy’s high blood...
- 11/30/11--23:30:_Ranbaxy’s relief after...
- 12/05/11--08:42:_Pharma still bullish on EMs
- 12/06/11--13:43:_Merck bets big on China
- 02/10/12--08:57:_Guest post: Building...
More Channels
- Feb 23: Gout Online Forums
- Feb 23: OutreachMagazine.com
- Nov 28: Happy to Be.
- Nov 18: gwadagyal971
- Nov 26: Mafia Manager. LJ edition
- Nov 27: mYY lIfE.my FRiend's
- Feb 22: やっぱりカレーはやめ...
- Nov 18: 3615 ma vie.sky'
- Dec 21: Foursecondsleft
- Aug 4: GunnScienceClub's Xanga
- Nov 18: Go with the flow
- Nov 28: Maëlys_L
- Feb 11: Marel - News
- Nov 26: M . C . A . L ( L )
- Jan 27: colombe58
- Feb 23: 人物
- Nov 28: Olympique de Marseille - OM -...
- Feb 13: 今日行ったところ、食...
- Jan 15: 'The Pleasaunce Post'
- Feb 6: Tawatchai fotoGrafo's
- Nov 18: VeNeZuElA
- Aug 4: GummieF's Xanga
- Nov 28: Tommy Schlong Blog Your source...
- Feb 17: backpage.com | services |...
- Nov 27: M l.le Erika - Commentaires
- Nov 28: Blog de Maeldu24
- Dec 16: 20Dollars2surf
- Nov 27: juste des mots ,juste des larmes...
- Nov 28: Maamzelle Marina <3
- Nov 28: HEEY LAA P0PULASS =D
- Aug 18: Related Websites
- Feb 21: digart.pl
- Nov 28: ツ Gaëlle ツ
- Nov 26: 沙漠中狂舞
- Feb 23: digart.pl
- Nov 19: Allby.info
- Feb 18: Fauxzen.com
- Jul 29: heatherp82's Photobucket media
- Jan 3: Delicious/nandito/wizzrss+rss
- Feb 21: L.A. Times - World News
- Nov 20: Magical doremi
- Nov 21: Narik'sblog
- Feb 21: backpage.com | services | fort...
- Nov 26: Elfen lied! - Commentaires
- Nov 20: gnowttam's Xanga
- Nov 26: Blog de Gold-life--x
- Nov 28: нѕм = нιgн ѕ¢нσσℓ...
- Nov 18: Womens Erotica Blog
- Nov 27: message de bienvenu - Commentaires
- Nov 28: loris
|
|
Are you the publisher? Claim this channel |
|
Channel Description:
Latest Articles in this Channel:
- 06/11/10--05:31: Deal of the day: GSK in $253m boost for Argentina (chan 1567035)
- 07/07/10--05:17: Deal of the day: Aspen looks to snap up unloved Sigma (chan 1567035)
- 07/30/10--02:39: Shareholders (and markets) scupper Charles River’s China deal (chan 1567035)
- 08/12/10--06:25: Ranbaxy: is India’s pharma trailblazer running out of steam? (chan 1567035)
- 08/27/10--00:13: India: from generics-maker to drug-developer? (chan 1567035)
- 09/16/10--09:45: Pharma companies reveal their EM secrets (chan 1567035)
- 10/20/10--10:30: Deal of the day: India-US medical link (chan 1567035)
- 11/04/10--10:30: Deal of the day: Hungarian pharma company goes west (chan 1567035)
- 11/15/10--07:33: Brazilian drugmaker snubs Portugal (chan 1567035)
- 12/03/10--05:45: West’s drugmakers look for China buys (chan 1567035)
- 12/13/10--00:51: Deal of the day: India’s $724m Moov (chan 1567035)
- 04/08/11--05:08: Deal of the day: Taisho acquires HOE for US$122m (chan 1567035)
- 05/16/11--01:30: Shanghai Pharma prices HK listing (chan 1567035)
- 05/17/11--09:23: Indian pharma sector: coming of age? (chan 1567035)
- 10/04/11--01:30: Moroccan tonic for Hikma (chan 1567035)
- 11/30/11--06:44: Ranbaxy’s high blood pressure day (chan 1567035)
- 11/30/11--23:30: Ranbaxy’s relief after FDA approval (chan 1567035)
- 12/05/11--08:42: Pharma still bullish on EMs (chan 1567035)
- 12/06/11--13:43: Merck bets big on China (chan 1567035)
- 02/10/12--08:57: Guest post: Building halal brands (chan 1567035)
By Thomas Williams of mergermarket GlaxoSmithKline’s US$253m cash acquisition of Laboratorios Phoenix, Argentina’s pharmaceutical business, is modest by the industry’s high standards but it is a not an insignificant show of confidence in the troubled South American country’s economy. Announcing …
By Hanna Gezelius and Mintoi Chessa-Florea of mergermarket A takeover offer by South Africa-based Aspen Pharmacare Holdings for Australian Sigma Pharmaceuticals for A$0.55 per share, which amounts to A$647m, (€435m) highlights two main recurrent themes that are being weaved in …
It would have been the biggest ever western takeover of a mainland Chinese company. But Charles River’s $1.6bn deal for WuXi PharmaTech is off. The shareholders, and the market, will almost certainly breathe a sigh of relief. The deal, which would …
Some top executives enjoy enormous longevity at the helm of Indian companies. That can’t be said these days of those at Ranbaxy Laboratories, a once family-owned pharmaceutical company that was bought by Japan’s Daiichi Sankyo two years ago. Since the …
By Girija Shivakumar and Amy Kazmin in New Delhi Indian pharmaceutical companies are often touting their potential for innovative drug discovery. Piramal, the Mumbai-based drug company which sold its generics drug business to Abbott for $3.7bn, recently said it expects …
Western pharmaceutical companies have been revealing more about their activities in emerging markets – and now they’re starting to see the benefits of that transparency. One London broker decided to upgrade GlaxoSmithKline this week following the release of more details about its sales in emerging economies, a move that highlighted the importance analysts are attaching …
The Indian advance into the global pharmaceutical and medical equipment market goes on. Following some big deals, here is a modest $54.6m transaction which brings together Opto Circuits, a Bangalore-based pharmaceutical technology company, and Cardiac Science, a Washington state cardiac devices maker. Opto announced on Tuesday that it’s buying Cardiac Sciences to boost its presence …
By Mintoi Chessa-Florea of mergermarket Women’s health is one of those speciality sectors that offers stable growth for pharmaceutical companies. It is therefore unsurprising that Hungary’s Gedeon Richter should want to make leaps into the sector. Today’s €236.5m acquisition of Grünenthal’s oral contraceptive (OC) portfolio will rank the Hungarian company – which has plans to …
Brazil’s fast economic growth is driving two parallel trends in the pharmaceutical industry. First, western companies – whose traditional markets are stagnating – are returning to the country. And second, their Brazilian counterparts, buoyed by the wave of domestic growth, are looking for foreign acquisitions. Yet, amid all this, there’s further humiliation for Portugal, Brazil’s …
By Patti Waldmeir in Shanghai and Andrew Jack in London From fashion to pharmaceuticals, the principle is the same: if a global company does not succeed in China these days, it will increasingly struggle to succeed at all. So predictably, the past few weeks have seen a bunch of mergers and acquisitions in the Chinese …
Global healthcare companies show no sign of losing interest in India. On Monday Reckitt Benckiser, the UK cleaning products group, announced it had acquired India’s Paras Pharmaceuticals for Rs32.6bn ($724m), in a move that will significantly increase RB’s emerging markets presence. In buying the maker of a range of brands, including a painkilling ointment called …
By Mai Mizuta and Natasha Khan of mergermarket Taisho Pharmaceutical has become the latest in a string of Japanese pharma companies to acquire an emerging market counterpart, as companies search for better prospects as their consumer bases shrink at home. On Thursday Taisho, the prescription and over-the-counter drug maker, announced the acquisition of Malaysia-based pharmaceutical …
While Chinese internet companies have been rushing to list in New York, and Chinese banks are set to raise billions with issues on the mainland this year, there’s one sector that looks rather underrepresented in the equity issuance whirlwind – healthcare. Shanghai Pharma – which announced the pricing of its Hong Kong IPO on Monday …
Indian pharmaceutical companies have gained an unflattering reputation of being generic drug makers with little to show in the way of new product development and innovation. But a few companies in the sector are beginning to break the mould. On Monday Glenmark, the Mumbai-listed pharmaceutical firm, signed a licensing agreement with Sanofi, the French pharmaceutical group, for …
Hikma Pharmaceuticals, the fast-growing Jordan-based drugs group hard hit by the Arab Spring, is trying to capitalise on the opportunities created by the political turmoil. Late on Monday it announced plans to buy a $111.2m controlling stake in Morocco’s Societe de Promotion Pharmaceutique du Maghreb (Promopharm) to secure access to one of the Arab world’s …
Wednesday should have been a great day for India’s largest pharmaceutical company, Ranbaxy Laboratories. After all, it is one of two companies that, come Thursday, will be allowed to sell a generic version of Lipitor, Pfizer’s blockbuster anti-cholesterol drug. Instead, shares in Ranbaxy, which had global sales of nearly $1.9bn last year, fell 3.88 per …
Shares of India’s biggest pharmaceutical company, Ranbaxy Laboratories, opened up 10.4 per cent on Thursday, following news that it had received FDA-approval to market its generic version of Pfizer’s anti-cholesterol drug, Lipitor. The approvals on Wednesday came at the last moment, just one day before Ranbaxy would be legally allowed to sell the drug, which …
By Mark Wembridge With the slowdown in the developed world hitting healthcare spending, pharmaceuticals companies are redoubling their efforts in emerging markets. Some of the world’s top pharma executives on Monday reiterated their faith in EMs, their blossoming talent base and their expanding healthcare markets. Speaking at the Financial Times Global Pharmaceutical and Biotech conference …
For all the news of growth slowdowns, drug companies still love EMs. Merck, the US pharmaceutical giant, announced on Tuesday it is building a $1.5bn R&D facility in Beijing. The move follows comments on Monday from Miles White, Abbott chief executive, that companies need to “ride the wave of [EM] growth“. Speaking at the Financial Times …
By Shelina Janmohamed of Ogilvy Noor The race is on to establish powerful international ‘halal brands’. The stakes are high: by some estimates, the global market for halal products is worth $500bn a year. But it’s a market strewn with …